What Does Nemifitide diTFA Mean?
MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre examine To judge multiple intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Principal demo objectives ended up To judge the security and tolerability of sifalimumab in dermatomyositis or polymyositis i